Browse HMGB1

Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome Cytoplasm Secreted Cell membrane Peripheral membrane protein Extracellular side Endosome Endoplasmic reticulum-Golgi intermediate compartment Note=In basal state predominantly nuclear. Shuttles between the cytoplasm and the nucleus (PubMed:12231511, PubMed:17114460). Translocates from the nucleus to the cytoplasm upon autophagy stimulation (PubMed:20819940). Release from macrophages in the extracellular milieu requires the activation of NLRC4 or NLRP3 inflammasomes (By similarity). Passively released to the extracellular milieu from necrotic cells by diffusion, involving the fully reduced HGMB1 which subsequently gets oxidized (PubMed:19811284). Also released from apoptotic cells (PubMed:16855214, PubMed:18631454). Active secretion from a variety of immune and non-immune cells such as macrophages, monocytes, neutrophils, dendritic cells and natural killer cells in response to various stimuli such as LPS and cytokines involves a nonconventional secretory process via secretory lysosomes (PubMed:12231511, PubMed:14532127, PubMed:15944249). Secreted by plasma cells in response to LPS (By similarity). Found on the surface of activated platelets (PubMed:11154118). An increased chromatin association is observed when associated with the adenovirus protein pVII (PubMed:27362237).
Domain PF00505 HMG (high mobility group) box
PF09011 HMG-box domain
Function

Multifunctional redox sensitive protein with various roles in different cellular compartments. In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. Proposed to be an universal biosensor for nucleic acids. Promotes host inflammatory response to sterile and infectious signals and is involved in the coordination and integration of innate and adaptive immune responses. In the cytoplasm functions as sensor and/or chaperone for immunogenic nucleic acids implicating the activation of TLR9-mediated immune responses, and mediates autophagy. Acts as danger associated molecular pattern (DAMP) molecule that amplifies immune responses during tissue injury (PubMed:27362237). Released to the extracellular environment can bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE, lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates cells through engagement of multiple surface receptors. In the extracellular compartment fully reduced HMGB1 (released by necrosis) acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine, and sulfonyl HMGB1 (released from apoptotic cells) promotes immunological tolerance (PubMed:23519706, PubMed:23446148, PubMed:23994764, PubMed:25048472). Has proangiogdenic activity (By similarity). May be involved in platelet activation (By similarity). Binds to phosphatidylserine and phosphatidylethanolamide (By similarity). Bound to RAGE mediates signaling for neuronal outgrowth (By similarity). May play a role in accumulation of expanded polyglutamine (polyQ) proteins such as huntingtin (HTT) or TBP (PubMed:23303669, PubMed:25549101). ; FUNCTION: Nuclear functions are attributed to fully reduced HGMB1. Associates with chromatin and binds DNA with a preference to non-canonical DNA structures such as single-stranded DNA, DNA-containing cruciforms or bent structures, supercoiled DNA and ZDNA. Can bent DNA and enhance DNA flexibility by looping thus providing a mechanism to promote activities on various gene promoters by enhancing transcription factor binding and/or bringing distant regulatory sequences into close proximity (PubMed:20123072). May have an enhancing role in nucleotide excision repair (NER) (By similarity). However, effects in NER using in vitro systems have been reported conflictingly (PubMed:19446504, PubMed:19360789). May be involved in mismatch repair (MMR) and base excision repair (BER) pathways (PubMed:15014079, PubMed:16143102, PubMed:17803946). May be involved in double strand break repair such as non-homologous end joining (NHEJ) (By similarity). Involved in V(D)J recombination by acting as a cofactor of the RAG complex: acts by stimulating cleavage and RAG protein binding at the 23 bp spacer of conserved recombination signal sequences (RSS) (By similarity). In vitro can displace histone H1 from highly bent DNA (By similarity). Can restructure the canonical nucleosome leading to relaxation of structural constraints for transcription factor-binding (By similarity). Enhances binding of sterol regulatory element-binding proteins (SREBPs) such as SREBF1 to their cognate DNA sequences and increases their transcriptional activities (By similarity). Facilitates binding of TP53 to DNA (PubMed:23063560). Proposed to be involved in mitochondrial quality control and autophagy in a transcription-dependent fashion implicating HSPB1; however, this function has been questioned (By similarity). Can modulate the activity of the telomerase complex and may be involved in telomere maintenance (By similarity). ; FUNCTION: In the cytoplasm proposed to dissociate the BECN1:BCL2 complex via competitive interaction with BECN1 leading to autophagy activation (PubMed:20819940). Involved in oxidative stress-mediated autophagy (PubMed:21395369). Can protect BECN1 and ATG5 from calpain-mediated cleavage and thus proposed to control their proautophagic and proapoptotic functions and to regulate the extent and severity of inflammation-associated cellular injury (By similarity). In myeloid cells has a protective role against endotoxemia and bacterial infection by promoting autophagy (By similarity). Involved in endosomal translocation and activation of TLR9 in response to CpG-DNA in macrophages (By similarity). ; FUNCTION: In the extracellular compartment (following either active secretion or passive release) involved in regulation of the inflammatory response. Fully reduced HGMB1 (which subsequently gets oxidized after release) in association with CXCL12 mediates the recruitment of inflammatory cells during the initial phase of tissue injury; the CXCL12:HMGB1 complex triggers CXCR4 homodimerization (PubMed:22370717). Induces the migration of monocyte-derived immature dendritic cells and seems to regulate adhesive and migratory functions of neutrophils implicating AGER/RAGE and ITGAM (By similarity). Can bind to various types of DNA and RNA including microbial unmethylated CpG-DNA to enhance the innate immune response to nucleic acids. Proposed to act in promiscuous DNA/RNA sensing which cooperates with subsequent discriminative sensing by specific pattern recognition receptors (By similarity). Promotes extracellular DNA-induced AIM2 inflammasome activation implicating AGER/RAGE (PubMed:24971542). Disulfide HMGB1 binds to transmembrane receptors, such as AGER/RAGE, TLR2, TLR4 and probably TREM1, thus activating their signal transduction pathways. Mediates the release of cytokines/chemokines such as TNF, IL-1, IL-6, IL-8, CCL2, CCL3, CCL4 and CXCL10 (PubMed:12765338, PubMed:18354232, PubMed:19264983, PubMed:20547845, PubMed:24474694). Promotes secretion of interferon-gamma by macrophage-stimulated natural killer (NK) cells in concert with other cytokines like IL-2 or IL-12 (PubMed:15607795). TLR4 is proposed to be the primary receptor promoting macrophage activation and signaling through TLR4 seems to implicate LY96/MD-2 (PubMed:20547845). In bacterial LPS- or LTA-mediated inflammatory responses binds to the endotoxins and transfers them to CD14 for signaling to the respective TLR4:LY96 and TLR2 complexes (PubMed:18354232, PubMed:21660935, PubMed:25660311). Contributes to tumor proliferation by association with ACER/RAGE (By similarity). Can bind to IL1-beta and signals through the IL1R1:IL1RAP receptor complex (PubMed:18250463). Binding to class A CpG activates cytokine production in plasmacytoid dendritic cells implicating TLR9, MYD88 and AGER/RAGE and can activate autoreactive B cells. Via HMGB1-containing chromatin immune complexes may also promote B cell responses to endogenous TLR9 ligands through a B-cell receptor (BCR)-dependent and ACER/RAGE-independent mechanism (By similarity). Inhibits phagocytosis of apoptotic cells by macrophages; the function is dependent on poly-ADP-ribosylation and involves binding to phosphatidylserine on the cell surface of apoptotic cells (By similarity). In adaptive immunity may be involved in enhancing immunity through activation of effector T cells and suppression of regulatory T (TReg) cells (PubMed:15944249, PubMed:22473704). In contrast, without implicating effector or regulatory T-cells, required for tumor infiltration and activation of T-cells expressing the lymphotoxin LTA:LTB heterotrimer thus promoting tumor malignant progression (By similarity). Also reported to limit proliferation of T-cells (By similarity). Released HMGB1:nucleosome complexes formed during apoptosis can signal through TLR2 to induce cytokine production (PubMed:19064698). Involved in induction of immunological tolerance by apoptotic cells; its pro-inflammatory activities when released by apoptotic cells are neutralized by reactive oxygen species (ROS)-dependent oxidation specifically on Cys-106 (PubMed:18631454). During macrophage activation by activated lymphocyte-derived self apoptotic DNA (ALD-DNA) promotes recruitment of ALD-DNA to endosomes (By similarity).

> Gene Ontology
 
Biological Process GO:0000737 DNA catabolic process, endonucleolytic
GO:0001667 ameboidal-type cell migration
GO:0001773 myeloid dendritic cell activation
GO:0001776 leukocyte homeostasis
GO:0001780 neutrophil homeostasis
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002200 somatic diversification of immune receptors
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002250 adaptive immune response
GO:0002262 myeloid cell homeostasis
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002347 response to tumor cell
GO:0002366 leukocyte activation involved in immune response
GO:0002407 dendritic cell chemotaxis
GO:0002418 immune response to tumor cell
GO:0002424 T cell mediated immune response to tumor cell
GO:0002437 inflammatory response to antigenic stimulus
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002507 tolerance induction
GO:0002521 leukocyte differentiation
GO:0002548 monocyte chemotaxis
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002643 regulation of tolerance induction
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002840 regulation of T cell mediated immune response to tumor cell
GO:0006265 DNA topological change
GO:0006266 DNA ligation
GO:0006282 regulation of DNA repair
GO:0006298 mismatch repair
GO:0006308 DNA catabolic process
GO:0006309 apoptotic DNA fragmentation
GO:0006310 DNA recombination
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006909 phagocytosis
GO:0006914 autophagy
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007254 JNK cascade
GO:0009306 protein secretion
GO:0010506 regulation of autophagy
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016444 somatic cell DNA recombination
GO:0017055 negative regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0019439 aromatic compound catabolic process
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030262 apoptotic nuclear changes
GO:0030335 positive regulation of cell migration
GO:0030336 negative regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031333 negative regulation of protein complex assembly
GO:0031349 positive regulation of defense response
GO:0032069 regulation of nuclease activity
GO:0032070 regulation of deoxyribonuclease activity
GO:0032071 regulation of endodeoxyribonuclease activity
GO:0032072 regulation of restriction endodeoxyribonuclease activity
GO:0032103 positive regulation of response to external stimulus
GO:0032392 DNA geometric change
GO:0032423 regulation of mismatch repair
GO:0032425 positive regulation of mismatch repair
GO:0032609 interferon-gamma production
GO:0032612 interleukin-1 production
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032649 regulation of interferon-gamma production
GO:0032652 regulation of interleukin-1 production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032675 regulation of interleukin-6 production
GO:0032689 negative regulation of interferon-gamma production
GO:0032732 positive regulation of interleukin-1 production
GO:0032733 positive regulation of interleukin-10 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032755 positive regulation of interleukin-6 production
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033151 V(D)J recombination
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034123 positive regulation of toll-like receptor signaling pathway
GO:0034162 toll-like receptor 9 signaling pathway
GO:0034163 regulation of toll-like receptor 9 signaling pathway
GO:0034165 positive regulation of toll-like receptor 9 signaling pathway
GO:0034655 nucleobase-containing compound catabolic process
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035711 T-helper 1 cell activation
GO:0036336 dendritic cell migration
GO:0040013 negative regulation of locomotion
GO:0040017 positive regulation of locomotion
GO:0042088 T-helper 1 type immune response
GO:0042093 T-helper cell differentiation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043254 regulation of protein complex assembly
GO:0043277 apoptotic cell clearance
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043371 negative regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043388 positive regulation of DNA binding
GO:0043410 positive regulation of MAPK cascade
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044270 cellular nitrogen compound catabolic process
GO:0045063 T-helper 1 cell differentiation
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045739 positive regulation of DNA repair
GO:0045785 positive regulation of cell adhesion
GO:0045862 positive regulation of proteolysis
GO:0045898 regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0046006 regulation of activated T cell proliferation
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046636 negative regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046639 negative regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0046700 heterocycle catabolic process
GO:0048771 tissue remodeling
GO:0048872 homeostasis of number of cells
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050701 interleukin-1 secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051047 positive regulation of secretion
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0051103 DNA ligation involved in DNA repair
GO:0051105 regulation of DNA ligation
GO:0051106 positive regulation of DNA ligation
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051271 negative regulation of cellular component movement
GO:0051272 positive regulation of cellular component movement
GO:0051403 stress-activated MAPK cascade
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055074 calcium ion homeostasis
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060326 cell chemotaxis
GO:0060633 negative regulation of transcription initiation from RNA polymerase II promoter
GO:0065004 protein-DNA complex assembly
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070897 DNA-templated transcriptional preinitiation complex assembly
GO:0071103 DNA conformation change
GO:0071593 lymphocyte aggregation
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071824 protein-DNA complex subunit organization
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072604 interleukin-6 secretion
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0097028 dendritic cell differentiation
GO:0097194 execution phase of apoptosis
GO:0097350 neutrophil clearance
GO:0097529 myeloid leukocyte migration
GO:1901361 organic cyclic compound catabolic process
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903532 positive regulation of secretion by cell
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1904951 positive regulation of establishment of protein localization
GO:1990774 tumor necrosis factor secretion
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000143 negative regulation of DNA-templated transcription, initiation
GO:2000146 negative regulation of cell motility
GO:2000147 positive regulation of cell motility
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000515 negative regulation of CD4-positive, alpha-beta T cell activation
GO:2000778 positive regulation of interleukin-6 secretion
GO:2001020 regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
GO:2001056 positive regulation of cysteine-type endopeptidase activity
GO:2001198 regulation of dendritic cell differentiation
GO:2001200 positive regulation of dendritic cell differentiation
Molecular Function GO:0000217 DNA secondary structure binding
GO:0000400 four-way junction DNA binding
GO:0000405 bubble DNA binding
GO:0001530 lipopolysaccharide binding
GO:0001786 phosphatidylserine binding
GO:0003684 damaged DNA binding
GO:0003697 single-stranded DNA binding
GO:0005125 cytokine activity
GO:0005543 phospholipid binding
GO:0008134 transcription factor binding
GO:0008301 DNA binding, bending
GO:0016829 lyase activity
GO:0019955 cytokine binding
GO:0019956 chemokine binding
GO:0019958 C-X-C chemokine binding
GO:0042056 chemoattractant activity
GO:0043566 structure-specific DNA binding
GO:0050786 RAGE receptor binding
GO:0070182 DNA polymerase binding
GO:0070491 repressing transcription factor binding
GO:0072341 modified amino acid binding
GO:0097100 supercoiled DNA binding
Cellular Component GO:0000793 condensed chromosome
GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0017053 transcriptional repressor complex
> KEGG and Reactome Pathway
 
KEGG hsa03410 Base excision repair
hsa04140 Regulation of autophagy
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-211227: Activation of DNA fragmentation factor
R-HSA-879415: Advanced glycosylation endproduct receptor signaling
R-HSA-109581: Apoptosis
R-HSA-140342: Apoptosis induced DNA fragmentation
R-HSA-75153: Apoptotic execution phase
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-6798695: Neutrophil degranulation
R-HSA-5357801: Programmed Cell Death
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HMGB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HMGB1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28274958Prostate CarcinomaPromote immunity (infiltration)This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor.
26289067MelanomaInhibit immunity (T cell function)Moreover, in nonresponders, moMDSCs produced significantly more nitric oxide, and granulocytic MDSCs expressed higher levels of PD-L1 than these parameters at baseline and in responders, suggesting their enhanced immunosuppressive capacity. Upon the first ipilimumab infusion, nonresponders displayed elevated serum concentrations of S100A8/A9 and HMGB1 that attract and activate MDSCs.
25492101Cervical CarcinomaInhibit immunity (T cell function)HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells.
27987020Breast carcinomaInhibit immunity (T and NK cell function); immunotherapy targetPrevious data indicate that high mobility group box 1(HMGB1) facilitates MDSC differentiation from bone marrow, suppresses NK cells, CD4+ and CD8+ T cells and is involved in cancer development. HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, Overepression of HMGB1 alter immune responses by suppressing NK cells, CD4+ and CD8+ T cells, and participate in cancer development. Monoclonal antibody targeting HMGB1 delay tumor growth and development, thus could be a possible immunotherapy target for breast carcinoma. MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients. All these data indicate that HMGB1 might be a potential tumor immunotherapy target.
23108142Prostate carcinomaPromote immunity (T cell function)In this study, we report that the production of HMGB1, an established DAMP released by dying cells, was critical for tumor progression in an established mouse model of prostate cancer. HMGB1 was required for the activation and intratumoral accumulation of T cells that expressed cytokine lymphotoxinα(1)β(2) (LT) on their surface. Taken together, our findings suggest that the release of HMGB1 as an endogenous danger signal is important for priming an adaptive immune response that promotes malignant progression, with implications for cancer prevention and therapy.
19143470GlioblastomaPromote immunity (T cell function)Specific activation of TLR2 signaling was induced by supernatants from Ad-TK (+GCV)-treated GBM cells; this activation was blocked by glycyrrhizin (a specific HMGB1 inhibitor) or with antibodies to HMGB1. HMGB1 was also released from melanoma, small cell lung carcinoma, and glioma cells treated with radiation or temozolomide. Administration of either glycyrrhizin or anti-HMGB1 immunoglobulins to tumor-bearing Ad-Flt3L and Ad-TK treated mice, abolished therapeutic efficacy, highlighting the critical role played by HMGB1-mediated TLR2 signaling to elicit tumor regression.
25012502Pancreatic ductal adenocarcinomaPromote immunity (T cell function)In addition, tumor cells died via intrinsic apoptosis and displayed features of immunogenic cell death, such as release of HMGB1 and translocation of calreticulin to the outer cell membrane.
29601471hepatocellular carcinomaPromote immunityuch effects may be responsible for release of danger-associated molecular patterns, including ATP, calreticulin, and high mobility group box 1 (HMBG1) from 4T1-Luc cells to induce immunogenic cell death (ICD).
29600445melanomaPromote immunityMoreover, heat-shock treatment of GBCCLs induced calreticulin translocation and release of HMGB1 and ATP, both known to act as danger signals.
29270668Rectal CarcinomaPromote immunityThe better outcome is likely due to the release of HMGB1, which triggers the maturation of dendritic cells (DCs) via TLR4 activation, and the subsequent recruitment of PD-1+?tumor-infiltrating lymphocytes to the tumor site, where they participate in immune-scavenging.
21642542Breast Carcinoma; Lung CarcinomaInhibit immunityKnockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. Short hairpin RNA-mediated knockdown of HMGB1 (HMGB1 KD) in tumor cells did not affect tumor cell growth but uncovered naturally acquired long-lasting tumor-specific IFN-γ- or TNF-α-producing CD8 T cell responses and attenuated their ability to induce Treg, leading to naturally acquired CD8 T cell- or IFN-γ-dependent tumor rejection. The data suggest that tumor cell-derived HMGB1 may suppress naturally acquired CD8 T cell-dependent antitumor immunity via enhancing Treg to produce IL-10, which is necessary for Treg-mediated immune suppression.
25164013breast carcinoma; colon carcinoma; melanoma; colon adenocarcinoma; prostate carcinomaInhibit immunityWe found that HMGB1 promotes the development of MDSCs from bone marrow progenitor cells, contributing to their ability to suppress antigen-driven activation of CD4(+) and CD8(+) T cells
16968820MelanomaPromote immunityHMGB1, along with other intracellular factors released from tumor cells induced by cytolysis, may be important components of the disordered tumor microenvironment.
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HMGB1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HMGB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0320.882
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0450.99
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0930.972
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1140.679
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0630.98
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1810.953
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1890.714
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2680.916
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0740.979
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3050.895
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2480.944
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1320.0738
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HMGB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMGB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMGB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMGB1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMGB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HMGB1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HMGB1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHMGB1
Namehigh mobility group box 1
Aliases HMG3; SBP-1; DKFZp686A04236; Sulfoglucuronyl carbohydrate binding protein; Amphoterin; high mobility group p ......
Chromosomal Location13q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HMGB1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HMGB1.
ID Name Drug Type Targets #Targets
DB05869Ethyl pyruvateSmall MoleculeHMGB1, TNF2